Depuy Orthopaedics Launches Pinnacle(TM) Hip Solutions With Trueglide(TM) Technology

DePuy Orthopaedics, Inc., a global leader
in devices for joint replacement, announced the launch of Pinnacle™ Hip Solutions
with TrueGlide™ technology, a portfolio of high performance instruments, advanced
implants, materials and solutions. Pinnacle Hip Solutions products are designed to
promote pain relief and a smooth range-of-motion. This new portfolio of hip products
offers surgeons more options and greater flexibility when performing hip replacement
surgery.


DePuy announced the company will also be launching a professional and consumer
education campaign about the science and clinical evidence behind the products. This
campaign will feature actual hip replacement patients, including legendary Duke
Basketball head coach Mike (Coach K) Krzyzewski, who has two DePuy hips.


DePuy Orthopaedics made the announcement here at the 75th Annual Meeting of the
American Academy of Orthopaedic Surgeons (AAOS), where it will showcase the new
Tri-Lock™ Bone Preservation Stem, AltrX™ LD liners and Biolox™ Delta TS ceramic
heads, all being introduced under the Pinnacle Hip Solutions banner.


"Pinnacle Hip Solutions is built for modern hip replacement patients who want long
lasting pain relief, a more fluid range of natural movement and a quicker recovery so they
can enjoy life again," said David Floyd, president of DePuy Orthopaedics. "DePuy
Orthopaedics will continue to advance the art and science of hip replacement with
products that help surgeons optimize patient outcomes."


At AAOS, DePuy Orthopaedics featured the Tri-Lock® Bone Preservation Stem, a new
Tapered-Wedge titanium stem that minimizes the amount of bone that needs to be
removed during hip replacement surgery, while promoting stability, preserving the
natural anatomy and restoring hip function.


The Tri-Lock Bone Preservation Stem has a reduced lateral shoulder, narrow geometry
and optimized length and can be used with minimally invasive techniques. Also, Tri-
Lock is coated with Gription™ fixation technology, a coating that provides consistent
implant seating height and improved initial stability and maximizes the potential for longterm
bony growth.


AltrX LD large diameter polyethylene liners and Biolox Delta TS ceramic heads were
also introduced, offering surgeons new choices for optimizing stability, reducing wear,
and providing greater longevity.


About Hip Replacement


According to the AAOS, the demand for hip replacement is growing rapidly. It is
estimated that the number of primary total hip replacements will increase by 174 percent
-- to 572,000 -- in 2030.1 This is due in part to the growing number of Baby Boomers
with osteoarthritis and the rise in obesity. For more information about hip replacement
visit DePuy's Web site hipreplacement.















About DePuy Orthopaedics, Inc.


DePuy Orthopaedics, Inc., a Johnson & Johnson company, is advancing the standard of
orthopaedic patient care, with a focused commitment to help surgeons achieve excellence in
surgical practice. The company designs, manufactures and distributes orthopaedic devices and
supplies including hip, knee, extremity, trauma, cement, orthobiologics, and operating room
products. As a global leader in joint replacement products, DePuy Orthopaedics is committed to
Restoring the Joy of Motion® for patients whose mobility is restricted by severe osteoarthritis or
other debilitating injury. For more information about DePuy Orthopaedics, Inc., visit the
company's Web site depuyorthopaedics.


This press release contains "forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from Johnson & Johnson's expectations and projections.
Risks and uncertainties include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws
and regulations; and trends toward health care cost containment. A further list and description of
these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual
Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as
well as subsequent filings, are available online at sec, jnj or on request from
Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking
statements as a result of new information or future events or developments.


Reference:


1. "Total Knee and Hip Replacement Surgery Projections Show Meteoric Rise by 2030.
Orthopaedic procedures set to continue gaining widespread acceptance as means to
restore quality-of-life," American Academy of Orthopaedic Surgeons (AAOS) Web site:
see here.

DePuy Orthopaedics, Inc.